[1]陈 晶,杜 娟,牛学琴,等.沙美特罗对COPD患者SaO2及肺功能的影响研究[J].医学信息,2018,31(20):42-44,48.[doi:10.3969/j.issn.1006-1959.2018.20.013]
　CHEN Jing,DU Juan,NIU Xue-qin,et al.Effect of Salmeterol on SaO2 and lung function in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(20):42-44,48.[doi:10.3969/j.issn.1006-1959.2018.20.013]
点击复制

沙美特罗对COPD患者SaO2及肺功能的影响研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年20期
页码:
42-44,48
栏目:
论著
出版日期:
2018-10-15

文章信息/Info

Title:
Effect of Salmeterol on SaO2 and lung function in Patients with Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2018）20-0042-04
作者:
陈 晶; 杜 娟; 牛学琴; 李孔龙; 柯亭羽
昆明医科大学第二附属医院内分泌科，云南 昆明 650101
Author(s):
CHEN Jing; DU Juan; NIU Xue-qin; LI Kong-long; KE Ting-yu
Department of Endocrinology,the Second Affiliated Hospital of Kunming Medical University,Kunming 650101,Yunnan,China
关键词:
慢性阻塞性肺疾病; 沙美特罗; 动脉氧饱和度; 睡眠质量
Keywords:
Chronic obstructive pulmonary disease; Salmeterol; Arterial oxygen saturation; Sleep quality
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2018.20.013
文献标志码:
A
摘要:
目的 观察吸入沙美特罗对慢性阻塞性肺疾病患者睡眠期动脉血氧饱和度和睡眠质量的影响。方法 选择我院2015年1月~12月慢性阻塞性肺疾病患者60例，随机分为沙美特罗组和对照组，各30例。沙美特罗组接受吸入沙美特罗治疗，对照组接受安慰剂治疗。比较两组患者的SaO2、睡眠质量指数和肺功能指标。结果 治疗后，沙美特罗组睡眠期SaO2为（93.03±7.43）%，对照组为（91.21±9.01）%，差异有统计学意义（P＜0.05）；且沙美特罗组睡眠期TST90为（2.40±0.4）%，对照组TST90为（19.53±1.72）%，差异有统计学意义（P＜0.05）。治疗后，沙美特罗组患者肺功能较对照组改善，沙美特罗组FRC为（5.70±0.49）L，对照组为（6.23±0.54）L，差异有统计学意义（P＜0.05）；两组睡眠质量指数比较，差异无统计学意义（P＞0.05）。结论 吸入沙美特罗可改善COPD患者睡眠期SaO2，对睡眠质量无显著影响。
Abstract:
Objective To observe the effect of inhaled salmeterol on arterial oxygen saturation and sleep quality in patients with chronic obstructive pulmonary disease during sleep.Methods 60 patients with chronic obstructive pulmonary disease from January to December 2015 in our hospital were randomly divided into salmeterol group and control group,30 cases each.The salmeterol group received inhaled salmeterol and the control group received placebo.SaO2,sleep quality index and lung function index were compared between the two groups.Results After treatment,the SaO2 in the salmeterol group was(93.03±7.43)%,the control group was(91.21±9.01)%,the difference was statistically significant(P<0.05);and the salmeterol group sleep period TST90 was(2.40±0.4)%,the control group TST90 was(19.53±1.72)%,the difference was statistically significant(P<0.05).After treatment,the lung function of the salmeterol group was improved compared with the control group,the FRC of the salmeterol group was(5.70±0.49)L,and the control group was (6.23±0.54)L,the difference was statistically significant(P<0.05);There was no significant difference in sleep quality index between the two groups(P>0.05).Conclusion Inhaled salmeterol can improve the sleep stage SaO2 in patients with COPD,and has no significant effect on sleep quality.

参考文献/References:

[1]Celli BR,MacNee W,Force AET.Standards for the diagnosis and treatment of patients with copd:A summary of the ats/ers position paper[J].Eur Respir J,2004,23(6):932-946. [2]Vestbo J,Lange P.Natural history of copd:Focusing on change in fev1[J].Respirology,2016,21(1):34-43. [3]徐新毅,刘友琴,徐丹,等.Rhoa相关信号通路的表达对COPD大鼠气道重塑的影响[J].贵州医药,2015,39(10):880-882. [4]Lacasse Y,Series F,Vujovic-Zotovic N,et al.Evaluating nocturnal oxygen desaturation in copd--revised[J].Respir Med,2011,105(9):1331-1337. [5]Budhiraja R,Siddiqi TA,Quan SF.Sleep disorders in chronic obstructive pulmonary disease:Etiology,impact,and management[J].J Clin Sleep Med,2015,11(3):259-270. [6]Brouillard C,Pepin V,Milot J,et al.Endurance shuttle walking test:Responsiveness to salmeterol in copd[J].Eur Respir J,2008,31(3):579-584. [7]中华医学会呼吸病分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病(COPD)的诊治指南[J].中华结核和呼吸杂志,2014,6(2):67-79. [8]Miravitlles M,Vogelmeier C,Roche N,et al.A review of national guidelines for management of copd in europe[J].Eur Respir J,2016,47(2):625-637. [9]Schnell K,Weiss CO,Lee T,et al.The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed copd:A cross-sectional study using data from nhanes 1999-2008[J].BMC Pulm Med,2012,12(26). [10]Valipour A,Lavie P,Lothaller H,et al.Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease[J].Sleep Med,2011,12(4):367-372. [11]Zangiabadi A,De Pasquale CG,Sajkov D.Pulmonary hypertension and right heart dysfunction in chronic lung disease[J]. Biomed Res Int,2014(2014):739674. [12]Alexandre F,Heraud N,Varray A.Is nocturnal desaturation a trigger for neuronal damage in chronic obstructive pulmonary disease[J].Med Hypotheses,2015,84(1):25-30. [13]季宏志,许西琳.基因多态性与慢性阻塞性肺疾病易感性关系研究的新进展[J].现代生物医学进展,2012,12(23):4569-4571. [14]McDonald CF.Oxygen therapy for copd[J].J Thorac Dis,2014,6(11):1632-1639. [15]Mayos M,Hernandez Plaza L,Farre A,et al.the effect of nocturnal oxygen therapy in patients with sleep apnea syndrome and chronic airflow limitation[J].Arch Bronconeumol,2001,37(2):65-68. [16]McNicholas WT,Calverley PM,Lee A,et al.Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in copd[J].Eur Respir J,2004,23(6):825-831. [17]Voduc N,Alvarez GG,Amjadi K,et al.Effect of theophylline on exercise capacity in copd patients treated with combination long-acting bronchodilator therapy:A pilot study[J].Int J Chron Obstruct Pulmon Dis,2012(7):245-252. [18]Tagaya E,Kondo M,Kirishi S,et al.Effects of regular treatment with combination of salmeterol fluticasone propionate and salmeterol alone in cough variant asthma[J].J Asthma,2015,52(5):512-518. [19]O’Donnell DE,Voduc N,Fitzpatrick M,et al.Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease[J].Eur Respir J,2004,24(1):86-94. [20]Short PM,Lipworth SI,Elder DH,et al.Effect of beta blockers in treatment of chronic obstructive pulmonary disease:A retrospective cohort study[J].Bmj,2011(342):d2549. [21]Wang J,Nie B,Xiong W,et al.Effect of long-acting beta-agonists on the frequency of copd exacerbations:A meta-analysis[J].J Clin Pharm Ther,2012,37(2):204-211. [22]Ganga HV,Nair SU,Puppala VK,et al.Risk of new-onset atrial fibrillation in elderly patients with the overlap syndrome:A retrospective cohort study[J].J Geriatr Cardiol,2013,10(2):129-134. [23]Mieczkowski B,Ezzie ME.Update on obstructive sleep apnea and its relation to copd[J].Int J Chron Obstruct Pulmon Dis,2014(9):349-362.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(20):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(20):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,31(20):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(20):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,31(20):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(20):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,31(20):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
　HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(20):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
[10]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(20):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]

更新日期/Last Update: 2018-11-09